Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

Newbury Pharmaceuticals AB (publ) (NEWBRY.ST) — VMCI valuation read

NEWBRY.ST screens at VMCI 34/100, a 16-point gap below the Healthcare sector median (50). For a mid-cap Newbury Pharmaceuticals AB (publ) share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

NEWBRY.ST has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: NEWBRY.ST trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.0x leaves covenant headroom, which sets the rate-cycle exposure for Newbury Pharmaceuticals AB (publ).

NEWBRY.ST rose 1.2% over the trailing 7 days, with a -3.1% read on a 30-day basis.